Vivian V. Liang BS, Alejandra Sataray-Rodriguez BS, Janae Rasmussen DO, Klaudia Greer BS, Shivam Shah BS, Laura Palma BA, MS, Kelly Frasier DO, MS, Pedram Razavi BS, Garrett Chin BS
{"title":"皮肤红斑狼疮和骨坏死的交叉:骨科关节保存的皮肤病学意义","authors":"Vivian V. Liang BS, Alejandra Sataray-Rodriguez BS, Janae Rasmussen DO, Klaudia Greer BS, Shivam Shah BS, Laura Palma BA, MS, Kelly Frasier DO, MS, Pedram Razavi BS, Garrett Chin BS","doi":"10.1016/j.jnma.2025.08.066","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The intersection of cutaneous lupus erythematosus (CLE) and osteonecrosis highlights a complex relationship between dermatologic and orthopedic pathology, underscoring the systemic nature of autoimmune disease. Osteonecrosis, characterized by ischemic bone death and subsequent joint degeneration, is a known complication in systemic lupus erythematosus (SLE), but emerging evidence suggests that CLE manifestations may serve as early indicators or contributory factors in its development. Chronic inflammation and microvascular injury, central to CLE pathophysiology, may predispose affected patients to compromised bone perfusion and ischemia, particularly in weight-bearing joints such as the hips and knees. Dermatologic signs, including persistent erythema, ulceration, or livedo reticularis, may reflect underlying vascular dysfunction that extends beyond the skin to subchondral bone, accelerating osteonecrotic processes. The role of autoantibodies, such as antiphospholipid antibodies, and their contribution to thrombotic microangiopathy in CLE further supports this potential mechanistic link. Early recognition of CLE-related vascular changes could guide orthopedic surveillance strategies, enabling timely imaging with MRI to detect early osteonecrosis before irreversible joint damage occurs.</div><div>Therapeutic interventions for CLE, including corticosteroids and immunosuppressive agents, may inadvertently exacerbate osteonecrosis risk, necessitating careful balancing of treatment efficacy with preservation of joint health. Advances in vascular- targeted therapies and bone-preserving interventions, such as bisphosphonates or regenerative techniques, offer potential avenues for mitigating joint degeneration in this patient population.</div></div><div><h3>Conclusion</h3><div>Understanding the bidirectional relationship between CLE and osteonecrosis provides an opportunity for dermatologists and orthopedists to collaborate on predictive, preventive, and therapeutic strategies that preserve joint function and improve quality of life for affected individuals.</div></div>","PeriodicalId":17369,"journal":{"name":"Journal of the National Medical Association","volume":"117 1","pages":"Pages 34-35"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Intersection of Cutaneous Lupus and Osteonecrosis: Dermatologic Implications for Orthopedic Joint Preservation\",\"authors\":\"Vivian V. Liang BS, Alejandra Sataray-Rodriguez BS, Janae Rasmussen DO, Klaudia Greer BS, Shivam Shah BS, Laura Palma BA, MS, Kelly Frasier DO, MS, Pedram Razavi BS, Garrett Chin BS\",\"doi\":\"10.1016/j.jnma.2025.08.066\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>The intersection of cutaneous lupus erythematosus (CLE) and osteonecrosis highlights a complex relationship between dermatologic and orthopedic pathology, underscoring the systemic nature of autoimmune disease. Osteonecrosis, characterized by ischemic bone death and subsequent joint degeneration, is a known complication in systemic lupus erythematosus (SLE), but emerging evidence suggests that CLE manifestations may serve as early indicators or contributory factors in its development. Chronic inflammation and microvascular injury, central to CLE pathophysiology, may predispose affected patients to compromised bone perfusion and ischemia, particularly in weight-bearing joints such as the hips and knees. Dermatologic signs, including persistent erythema, ulceration, or livedo reticularis, may reflect underlying vascular dysfunction that extends beyond the skin to subchondral bone, accelerating osteonecrotic processes. The role of autoantibodies, such as antiphospholipid antibodies, and their contribution to thrombotic microangiopathy in CLE further supports this potential mechanistic link. Early recognition of CLE-related vascular changes could guide orthopedic surveillance strategies, enabling timely imaging with MRI to detect early osteonecrosis before irreversible joint damage occurs.</div><div>Therapeutic interventions for CLE, including corticosteroids and immunosuppressive agents, may inadvertently exacerbate osteonecrosis risk, necessitating careful balancing of treatment efficacy with preservation of joint health. Advances in vascular- targeted therapies and bone-preserving interventions, such as bisphosphonates or regenerative techniques, offer potential avenues for mitigating joint degeneration in this patient population.</div></div><div><h3>Conclusion</h3><div>Understanding the bidirectional relationship between CLE and osteonecrosis provides an opportunity for dermatologists and orthopedists to collaborate on predictive, preventive, and therapeutic strategies that preserve joint function and improve quality of life for affected individuals.</div></div>\",\"PeriodicalId\":17369,\"journal\":{\"name\":\"Journal of the National Medical Association\",\"volume\":\"117 1\",\"pages\":\"Pages 34-35\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Medical Association\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0027968425002627\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Medical Association","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0027968425002627","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
The Intersection of Cutaneous Lupus and Osteonecrosis: Dermatologic Implications for Orthopedic Joint Preservation
Introduction
The intersection of cutaneous lupus erythematosus (CLE) and osteonecrosis highlights a complex relationship between dermatologic and orthopedic pathology, underscoring the systemic nature of autoimmune disease. Osteonecrosis, characterized by ischemic bone death and subsequent joint degeneration, is a known complication in systemic lupus erythematosus (SLE), but emerging evidence suggests that CLE manifestations may serve as early indicators or contributory factors in its development. Chronic inflammation and microvascular injury, central to CLE pathophysiology, may predispose affected patients to compromised bone perfusion and ischemia, particularly in weight-bearing joints such as the hips and knees. Dermatologic signs, including persistent erythema, ulceration, or livedo reticularis, may reflect underlying vascular dysfunction that extends beyond the skin to subchondral bone, accelerating osteonecrotic processes. The role of autoantibodies, such as antiphospholipid antibodies, and their contribution to thrombotic microangiopathy in CLE further supports this potential mechanistic link. Early recognition of CLE-related vascular changes could guide orthopedic surveillance strategies, enabling timely imaging with MRI to detect early osteonecrosis before irreversible joint damage occurs.
Therapeutic interventions for CLE, including corticosteroids and immunosuppressive agents, may inadvertently exacerbate osteonecrosis risk, necessitating careful balancing of treatment efficacy with preservation of joint health. Advances in vascular- targeted therapies and bone-preserving interventions, such as bisphosphonates or regenerative techniques, offer potential avenues for mitigating joint degeneration in this patient population.
Conclusion
Understanding the bidirectional relationship between CLE and osteonecrosis provides an opportunity for dermatologists and orthopedists to collaborate on predictive, preventive, and therapeutic strategies that preserve joint function and improve quality of life for affected individuals.
期刊介绍:
Journal of the National Medical Association, the official journal of the National Medical Association, is a peer-reviewed publication whose purpose is to address medical care disparities of persons of African descent.
The Journal of the National Medical Association is focused on specialized clinical research activities related to the health problems of African Americans and other minority groups. Special emphasis is placed on the application of medical science to improve the healthcare of underserved populations both in the United States and abroad. The Journal has the following objectives: (1) to expand the base of original peer-reviewed literature and the quality of that research on the topic of minority health; (2) to provide greater dissemination of this research; (3) to offer appropriate and timely recognition of the significant contributions of physicians who serve these populations; and (4) to promote engagement by member and non-member physicians in the overall goals and objectives of the National Medical Association.